NO930199L - OLIGONUCLEOTIDE ANALOGS, THEIR PREPARATION AND USE - Google Patents

OLIGONUCLEOTIDE ANALOGS, THEIR PREPARATION AND USE

Info

Publication number
NO930199L
NO930199L NO93930199A NO930199A NO930199L NO 930199 L NO930199 L NO 930199L NO 93930199 A NO93930199 A NO 93930199A NO 930199 A NO930199 A NO 930199A NO 930199 L NO930199 L NO 930199L
Authority
NO
Norway
Prior art keywords
aryl
alkyl
preparation
seh
alkoxy
Prior art date
Application number
NO93930199A
Other languages
Norwegian (no)
Other versions
NO308215B1 (en
NO930199D0 (en
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Gerard O'malley
Matthias Helsberg
Irvin Winkler
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO930199D0 publication Critical patent/NO930199D0/en
Publication of NO930199L publication Critical patent/NO930199L/en
Publication of NO308215B1 publication Critical patent/NO308215B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to compounds of the formula I <IMAGE> in which R<1> is H, alkyl, acyl, aryl or a phosphate residue; R<2> is H, OH, alkoxy, NH2 or halogen; B is a base customary in nucleotide chemistry; a is O or CH2; n is an integer from 1 to 100; W is O, S or Se; V is O, S or NH; Y is O, S, NH or CH2; Y' is O, S, NH or alkylene; X is OH or SH; U is OH, SH, SeH, alkyl, aryl or amine, and Z is OH, SH, SeH, an optionally substituted radical from the series comprising alkyl, aryl, heteroaryl, alkoxy or amino or a group which favours intracellular uptake or as labelling of a DNA probe or which on hybridisation interacts with the target nucleic acid, where if Z is OH, SH, CH3 or OC2H5, at least one of the groups X, Y, Y', V, W is not equal to OH or O, or R<1> is not equal to H; process for their preparation and their use as inhibitors of gene expression, as probes for detecting nucleic acids and as aids in molecular biology.
NO930199A 1992-01-22 1993-01-21 Oligonucleotide analogues, their use and pharmaceutical composition containing them NO308215B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4201662 1992-01-22

Publications (3)

Publication Number Publication Date
NO930199D0 NO930199D0 (en) 1993-01-21
NO930199L true NO930199L (en) 1993-07-23
NO308215B1 NO308215B1 (en) 2000-08-14

Family

ID=6450030

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930199A NO308215B1 (en) 1992-01-22 1993-01-21 Oligonucleotide analogues, their use and pharmaceutical composition containing them

Country Status (17)

Country Link
EP (1) EP0552766B1 (en)
JP (1) JP3717081B2 (en)
KR (1) KR930016437A (en)
AT (1) ATE217880T1 (en)
AU (1) AU661365B2 (en)
CA (1) CA2087818C (en)
DE (1) DE59310285D1 (en)
DK (1) DK0552766T3 (en)
ES (1) ES2177532T3 (en)
FI (1) FI115214B (en)
HU (1) HU227794B1 (en)
IL (1) IL104461A (en)
NO (1) NO308215B1 (en)
NZ (1) NZ245720A (en)
PL (1) PL172257B1 (en)
PT (1) PT552766E (en)
ZA (1) ZA93422B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DE59306170D1 (en) * 1992-09-24 1997-05-22 Hoechst Ag Oligoribonucleotide and ribozyme analogs with terminal 3'-3 'and 5'-5' linkages
EP0602524A1 (en) * 1992-12-15 1994-06-22 Hoechst Aktiengesellschaft Chemiluminescence marked sequences and their use in sequence testing
ATE150464T1 (en) * 1993-01-08 1997-04-15 Hybridon Inc SYNTHESIS OF DIMER BLOCKS AND THEIR USE IN THE COMPOSITION OF OLIGONUCLEOTIDES
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
NZ262254A (en) * 1993-01-25 1997-10-24 Hybridon Inc Oligonucleotide analogue containing a ribonucleotide alkylphosphon(ate or thioate), gene repression
CA2114355A1 (en) * 1993-01-29 1994-07-30 Hidehiko Furukawa Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (en) * 1993-09-17 1995-03-23 Hoechst Ag Antisense oligonucleotides against HSV-1 and the preparation thereof
DE4338704A1 (en) 1993-11-12 1995-05-18 Hoechst Ag Stabilized oligonucleotides and their use
DE4408528A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag Peptide oligonucleotide derivatives, their preparation and use
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
AU704549B2 (en) * 1994-03-18 1999-04-29 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4415370A1 (en) * 1994-05-02 1995-11-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (en) * 1994-11-04 1996-05-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
DE19502912A1 (en) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilized Oligonucleotides
DE59607750D1 (en) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoester nucleic acids, process for their preparation and their use
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) * 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
ES2221942T3 (en) * 1996-05-24 2005-01-16 Aventis Pharma Deutschland Gmbh REAGENT AND METHOD TO INHIBIT THE EXPRESSION OF N-RAS.
DE19627898A1 (en) * 1996-07-11 1998-01-15 Hoechst Ag Solid phase synthesis of oligonucleotides
WO1998050540A1 (en) * 1997-05-05 1998-11-12 Hoechst Marion Roussel Deutschland Gmbh MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE
AU9460898A (en) * 1997-10-14 1999-05-03 Sankyo Company Limited Modified oligodeoxyribonucleotides having tggg sequence
EP1004661A1 (en) 1998-11-11 2000-05-31 DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG High density granule, method for production thereof, and its use as disintegrant in tablets
DE19935303A1 (en) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonucleotides to inhibit the expression of human eg5
DE19935302A1 (en) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Conjugates and processes for their preparation and their use for the transport of molecules across biological membranes
DE10133915A1 (en) 2001-07-12 2003-02-06 Aventis Pharma Gmbh New oligoribonucleotide derivatives for targeted inhibition of gene expression
MXPA06002216A (en) 2003-08-28 2006-04-27 Novartis Ag INTERFERING RNA DUPLEX HAVING BLUNT-ENDS AND 3aCO-MODIFICATIONS.
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
CN104975020B (en) 2008-02-11 2020-01-17 菲奥医药公司 Modified RNAi polynucleotides and uses thereof
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
WO2015125845A1 (en) * 2014-02-20 2015-08-27 塩野義製薬株式会社 Phosphate site modification of nucleic acid containing nitrogen-containing non-aromatic heterocycle
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
WO2016037071A2 (en) 2014-09-05 2016-03-10 Rxi Pharmaceuticals Corporation Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
CN109563509B (en) 2015-10-19 2022-08-09 菲奥医药公司 Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239888A1 (en) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster METHOD FOR PRODUCING OLIGONUCLEOSIDE PHOSPHONATES
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4950745A (en) * 1986-10-30 1990-08-21 Daicel Chemical Industries, Ltd. Process for synthesis of oligonucleotides and compound for forming polymeric protecting group
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
EP0942000B1 (en) * 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) * 1990-10-04 1990-11-21 Ici Plc Synthesis of oligonucleotides

Also Published As

Publication number Publication date
HU227794B1 (en) 2012-03-28
ATE217880T1 (en) 2002-06-15
NZ245720A (en) 1995-12-21
HUT63173A (en) 1993-07-28
KR930016437A (en) 1993-08-26
FI930220A (en) 1993-07-23
AU661365B2 (en) 1995-07-20
FI930220A0 (en) 1993-01-20
EP0552766A2 (en) 1993-07-28
HU9300162D0 (en) 1993-04-28
IL104461A0 (en) 1993-05-13
PT552766E (en) 2002-10-31
DE59310285D1 (en) 2002-06-27
JP3717081B2 (en) 2005-11-16
AU3191093A (en) 1993-07-29
CA2087818C (en) 2007-07-10
ES2177532T3 (en) 2002-12-16
EP0552766B1 (en) 2002-05-22
DK0552766T3 (en) 2002-08-19
JPH05310779A (en) 1993-11-22
IL104461A (en) 2001-05-20
EP0552766A3 (en) 1994-09-07
FI115214B (en) 2005-03-31
NO308215B1 (en) 2000-08-14
NO930199D0 (en) 1993-01-21
ZA93422B (en) 1993-09-16
PL172257B1 (en) 1997-08-29
PL297515A1 (en) 1993-09-06
CA2087818A1 (en) 1993-07-23

Similar Documents

Publication Publication Date Title
NO930199L (en) OLIGONUCLEOTIDE ANALOGS, THEIR PREPARATION AND USE
US5317098A (en) Non-radioisotope tagging of fragments
Sinha et al. β-Cyanoethyl N, N-dialkylamino/N-morpholinomonochloro phosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of synthesized oligonucleotides
DE69815342D1 (en) SULFONATE-FREE CYANINE DYES FOR MARKING NUCLEOSIDES AND NUCLEOTIDES
ATE172468T1 (en) SYNTHETIC CATALYTIC OLIGONUCLEOTIDES
DE69415343T2 (en) 2&#39;-AMIDO AND 2&#39;-PEPTIDO-MODIFIED OLIGONUCLEOTIDES
ES2179080T3 (en) POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, ITS PREPARATION AND USE.
DE60002989D1 (en) PROCESS FOR THE PREPARATION OF MORPHOLINONUCLEOTIDES AND THE USE THEREOF FOR THE ANALYSIS AND MARKING OF NUCLEIC ACID SEQUENCES
ATE55109T1 (en) CHEMICAL PROCESS FOR THE PREPARATION OF OXAMIDE DERIVATIVES.
EP0462224B1 (en) Sequencing nucleic acids using chemiluminescent detection
KR970707144A (en) Amino acid nucleic acid (AMINO ACID NUCLEIC ACIDS)
DE69501705D1 (en) Process for the preparation of optically active piperazine derivatives and intermediates for their manufacture
DK1296997T3 (en) base analogues

Legal Events

Date Code Title Description
MK1K Patent expired